Chronic Fatigue Syndrome (CFS or ME) has always been a label that must have underlying causes. I have believed for years that one cause is low T3-effect within the cells. I myself was diagnosed with CFS, but I got well using T3-Only therapy. I wrote about this in my first book, 'Recovering with T3', and early on in the life of this blog.
This interesting article is entitled 'Pure T3 Thyroid and Stories of Recovery from Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia: An Overview.', I think you'll find it interesting:
Here is a another new piece of research (2019) that provides more scientific support for what I have been saying for many years.
T3 is critical to the workings of the pituitary gland. Without adequate T3 the pituitary is susceptible to dysfunction, and the anterior pituitary hormones may be affected. These hormones include ACTH, which drives both cortisol and Dhea production in the adrenal glands.
This is another piece of data that supports the protocol I developed in the Recovering with T3 book, i.e. CT3M:
This is a health study that implies that FT4 and FT3 levels when in a good range are protective of health. FT3 and FT4 tend to protect again many sources of mortality including cardiovascular related mortality. FT3 levels especially being at a good level protect against cancer.
We have a dark and insidious situation developing in the UK.
It is also happening in other countries.
Just as we appear to have more and more pieces of medical research that begin to show that T3 (Liothyronine) is necessary for some thyroid patients there is a shift against T3 from many endocrinologists and funding areas (Clinical Commission Groups, or CCGs, in the UK).
Why is it foolish to rigidly apply the FT3 lab reference range for people on T3-Only, and probably for those on T4/T3 and NDT too?
Almost all doctors think the FT3 reference range should always be abided by, i.e. an FT3 result should always be in range. Most patients agree with this approach too - as it is what they are often told.
Often the effect of doing this is that patient's T3 medication is never increased to a therapeutic dose, or it may even be reduced if FT3 is above the top of the range. So, why isn't this ok?